The STD Prevention Conference virtual platform is now live.
Access the virtual platform here.
Continuing Education (CE)Continuing Education (CE) credits will be available for all Plenary, Mini-Plenary, and Clinical Case Series. Attendees will have up until October 23, 2022, 11:59PM (ET) to apply for CE (please understand that no extensions beyond the deadline will be granted under any circumstance). Please see below, instructions for obtaining CE credits, and other additional information related to CE.
Instructions for Obtaining Continuing Education (CE)Available CE: CME, CNE, CEU, CPH, CHES
In order to receive continuing education (CE) for CM 4528 - 2022 STD Prevention Virtual Conference – September 19-22, 2022, please visit TCEO and follow these 9 Simple Steps before October 23, 2022*.
Course: CM 4528 - 2022 STD Prevention Virtual Conference – September 19-22, 2022
Course Access Code: 2022 STD Prevention Conference (Note: Course access code is case sensitive)
Course Detail: https://tceols.cdc.gov/Course/Detail2/8740
Complete the Evaluation at www.cdc.gov/GetCE for each session you attended and then complete the Entire Conference Evaluation
CE Certificate: Visit the Completed CE section of the My Activities page to download your certificate
There are no fees for CE activities.
OBJECTIVESParticipants should be able to:
1. Discuss at least two examples of strategies that can enhance STD prevention and control efforts.
2. Discuss at least two examples of STD-epidemiological trends and of clinical management for the sexually transmitted infections covered.
3. Describe how at least two factors within the health services system can affect STD prevention and treatment services.
4. Describe at least two social and behavioral aspects of STD prevention.
5. List two ways to improve interprofessional collaboration in scientific research, public health program and clinical management, to enhance STD prevention and control.
ACCREDITATION STATEMENTSIn support of improving patient care, this activity has been planned and implemented by Centers for Disease Control and Prevention and National Coalition of STD Directors (NCSD). The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention designates this activity for 6.5 nursing contact hours.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.7 CEU's for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 6.5 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. Continuing Competency credits available are 0. CDC provider number 98614.
For Certified Public Health Professionals (CPH)The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 7 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies with the exception of Dr. Barnbas and she wishes to disclose that Regeneron Pharmaceutical covered the cost of conference abstract and manuscript writing; and with the exception of Dr. Geisler and he wishes to disclose he is a Consultant and recipient of research funding for Hologic, Inc.; and with the exception of Dr. Hazra and she wishes to disclose she receives the Unrestricted Grant Funding from Gilead Sciences; and with the exception of Dr. Johnston and she wishes to disclose she receives grant from Gilead, consults for GSK, and receives royalties from UpToDate; and with the exception of Dr. Mbuagbaw and he wishes to disclose that he is a Consultant with Astra Zeneca; and with the exception of Dr. McNeil and she wishes to disclose she has a Contract Clinical Trial with BARDA/GSK, receives grant from Gilead, Hologic; and with the exception of Dr. Poteat and she wishes to disclose that she is a consultant (HIV Research Studies) for ViiV; and with the exception of Dr. Ramchandani and she wishes to disclose that she is a stockholder of Gilead and Merck . All relevant financial relationships listed for these individuals have been mitigated.
Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of: Dr. Barnabas’s discussion on Single-Dose HPV Vaccine, she will be discussing Efficacy of Single-Dose HPV Vaccination Among Young African Women; and with the exception of Dr. Geisler’s discussion of potential off-label use of FDA approved antibiotics for salvage therapy for M. genitalium infection; and with the exception of Dr. Singh’s discussion that may include reference to investigational rapid test kits for syphilis and HIV which will be clearly stated.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.